<DOC>
	<DOC>NCT03070314</DOC>
	<brief_summary>In this bioavailability trial should be shown that the one of the main active constituent in alcoholic echinacea extracts, the alkylamide dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamide (short: tetraen) is bioavailable in children of different age groups after intake of 5 Echinaforce junior tablets.</brief_summary>
	<brief_title>Echinaforce Junior Bioavailability Trial</brief_title>
	<detailed_description>In this bioavailability trial should be shown that the one of the main active constituent in alcoholic echinacea extracts, the alkylamide dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamide (short: tetraen) is bioavailable in children of different age groups after intake of 5 Echinaforce junior tablets. Six capillary blood draws are taken at the following time points: Start (0), after 15, 30, 60, 90, 270 minutes and thereafter the bioavailability is measured and calculated.</detailed_description>
	<mesh_term>Common Cold</mesh_term>
	<criteria>Children in the age group 412 years with an uncomplicated common cold (upper respiratory tract infection) First symptoms appeared within the last 72 hours Written consent given by the parents and verbal consent of children who are capable of judgement Not able to fast 2 hours prior to the treatment intake of another preparation containing echinacea within the last 24 hours Participation in a clinical trial within the last 30 days any progressive systemic illness, including tuberculosis, leukemia, connective tissue diseases, multiple sclerosis, or other autoimmune diseases; or history of relevant allergy, including allergy to Compositae plants</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Echinacea</keyword>
	<keyword>bioavailability</keyword>
	<keyword>children</keyword>
</DOC>